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Abstract
Background: Rotavirus has been identified as the most common pathogen associated with severe diarrhoea. Two
effective vaccines against the pathogen have been licensed. However, many countries including Indonesia have yet
to introduce the vaccine into their national immunisation programs. This study aimed to examine the attitudes of
healthcare providers (HCPs) and other health stakeholders towards the pathogen and the vaccine.
Methods: Semi-structured in-depth interviews were undertaken in two districts of Yogyakarta Province, Indonesia with
nurses, midwives, primary care providers, pediatricians and other health stakeholders. Thematic analysis was undertaken.
Results: Fourteen interviews were conducted between August and October 2013. We identified that while participants
do not consider diarrhea to be an important problem in Indonesia, they do acknowledge that it can be serious if not
properly treated. While the majority had some level of knowledge about rotavirus, not all participants knew that a vaccine
was available. There were mixed feelings towards the need for the vaccine. Some felt that the vaccine is not ranked as a
priority as it is not listed on the national program. However, others agreed there is a rationale for its use in Indonesia. The
cost of the vaccine (when sold in the private sector) was perceived to be the primary barrier impacting on its use.
Conclusions: The high cost and the low priority given to this vaccine by the public health authorities are the biggest
obstacles impacting on the acceptance of this vaccine in Indonesia. HCPs need to be reminded of the burden of disease
associated with rotavirus. In addition, reminding providers about the costs associated with treating severe cases versus
the costs associated with prevention may assist with improving the acceptance of HCPs towards the vaccine. Promotion
campaigns need to target the range of HCPs involved in the provision of care to infants and pregnant women.
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Background
Since the availability of the rotavirus vaccines, data on
the burden of rotavirus diarrhea and the efficacy of the
vaccines in low and middle-income settings has in-
creased, highlighting the positive impact of vaccination
on severe rotavirus disease. Following the introduction
of the vaccine, substantial declines in rotavirus and all-
cause diarrhea hospitalizations have been documented in
many countries [1].
The World Health Organization (WHO) recommends
the use of rotavirus vaccines in routine immunization pro-
grams worldwide [2]. However to date, the vaccines have
not been introduced into the national immunization pro-
grams (NIP) of countries in Asia and only to a limited
extent in Africa despite the high burden of severe
rotavirus-associated diarrhea in these continents. In
Indonesia, the rotavirus vaccine is recommended but is not
publicly funded; therefore vaccine uptake depends largely
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upon whether healthcare providers (HCPs) recommend it
to parents and its affordability.
To assist policymakers in deciding whether the vaccine
should be introduced into a national program, it is import-
ant to get an understanding of the perspectives of con-
sumers and providers’, as well as an understanding of their
acceptance towards it use and any perceived issues. The
importance of gathering this information is supported by
the WHO guidelines for vaccine introduction which
stresses that ‘the perceptions of the public and the medical
community about the disease and the vaccine should be an
important factor in determining its priority’ [3]. Given the
ongoing call to include rotavirus into national vaccination
programs, a program of research was instigated in
Yogyakarta, Indonesia to examine the knowledge, percep-
tions, and attitudes of community members, HCPs and
religious/community leaders toward rotavirus and the vac-
cine. This study reports on the findings from the HCP
interviews.
Methods
Study design and sample
In-depth interviews were conducted between August and
October 2013 targeting a range of HCPs in two districts of
Yogyakarta Province. The cities of Yogyakarta and Sleman
were chosen as they represented an urban and a rural
area. Ethics approval was sought and received from the
Human Research Ethics Committees at the Universitas
Gadjah Mada (UGM) and from the University of New
South Wales (UNSW), Sydney, Australia.
Participants
Health providers were purposively selected to increase the
richness of the information collected during the interviews:
nurses, midwives, primary care providers and pediatricians.
Participants were required to be aged 18 years and older
and to be able to provide informed consent. Potential par-
ticipants were recruited from two primary healthcare set-
tings, from one private practice and from two hospitals
(one academic teaching hospital and one private hospital).
In addition, senior members of a number of professional
health provider associations (including midvives and
pediatric nursing) and health department members were
also invited.
Data collection
The authors, based on a review of the literature, developed
an interview guide. Questions related to the following
topics: (1) knowledge and attitudes towards diarrhea; (2)
perceptions and experience with vaccines included/not in-
cluded on the national immunization program (NIP); (3)
knowledge of rotavirus diarrhea and vaccine; (4) acceptance
of the rotavirus vaccine; (5) barriers impacting vaccination
and (6) information needs and strategies for the provision
of information. After ascertaining whether the participant
had any baseline knowledge about rotavirus, a brief explan-
ation regarding the epidemiology of rotavirus diarrhea was
provided. In addition, a statement about the vaccine pro-
duction process was also provided to participants.
Paraphrasing and additional questions were added to
seek clarification during the interviews. Prompts were only
given when the interviewer deemed that it is necessary to
encourage the conversation back to topic or to address a
certain issue. During the interviews, member checking
was conducted to ensure rigor of research and that partic-
ipants views were accurately reported [4]. This involved
summarizing and feeding back participants’ views at the
end of the interview to compare the investigator’s account
with participants’ views. We continued with recruitment
until we reached data saturation, where no new ideas or
issues were raised in subsequent sessions [5]. Interviews
were conducted by researchers from Universities Gadjah
Mada in the local language.
Analysis
All interviews were audio recorded, transcribed verbatim,
translated into English and analyzed thematically. Tran-
scripts for each taped interview were checked for internal
consistency and corroborated with other interviews. The
researchers used NVivo 10 for the analysis [6]. Following
repeated and close reading of the individual interview
transcripts, the researchers independently constructed a
code list of major themes emerging from the data. These
code lists were compared and crosschecked and a final list
was compiled. An agreed thematic framework was then
applied to another subsample of transcripts and further
modified. Using this final framework, all of the 14 tran-
scripts were analyzed and coded.
Results
A total of 14 interviews were undertaken with three pedia-
tricians, four primary care providers, four midwives, and
three nurses. Participants worked in both public and pri-
vate settings and had a range of experience in the provision
of healthcare ranging from three to over twenty years. The
interview results are presented thematically below.
Not the number one problem
Participants acknowledge that diarrhea was an important
health issue in Indonesia; however they did not rate it as
the number one health problem. Instead they spoke of
tuberculosis, respiratory illnesses, leptospirosis, and dia-
betes as being the high priority diseases. Episodes of diar-
rhea were associated with poor hygiene and sanitation,
waste on the street and lack of clean drinking water. It
was acknowledged that rotavirus affects people at every
socio-economic level.
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Some participants felt that with the correct treat-
ment (i.e. rehydration, zinc), diarrhea was not consid-
ered dangerous. However, it was acknowledged that it
could be life threatening if not managed promptly.
Amongst the general public, the level of knowledge
about dealing with diarrhea was assumed to be good,
however it was suggested that parents don’t always
have the financial capacity to take their children to a
physicians and they may only see a midwives which
could result in the child not receiving the appropriate
level of treatment/care.
“…Diarrhea can be serious if the treatment is incorrect
but the main point is you have to do rehydration
therapy. For me, any kind of diarrhea is not that
dangerous as long as we can provide rehydration
therapy” (Midwife)
When asked about the strategies to prevent diarrhea,
eating healthy food, breastfeeding, living well, and adhering
to good hygiene practices were proposed. Very few spoke
about vaccination as a preventative strategy. However, the
general notion that prevention was better than treatment
was voiced by some of the participants.
Low levels of awareness and knowledge
Amongst the midwives and nurses interviewed there was
very little knowledge about rotavirus and/or the vaccine.
One of the nurses reported that she has not previously
heard the word ‘rotavirus’ until described by the inter-
viewer. In regards to the vaccine, other midwives and
nurses reported their knowledge to be limited and all they
knew was the vaccine was used to prevent diarrhea caused
by rotavirus. All of the physicians reported that they knew
about the pathogen and the vaccine. According to the
HCPs interviewed, the community also has very little
knowledge and/or awareness about the pathogen and the
availability of the vaccine. It was suggested that further
training be given to primary care providers and midwives
in order to clinically identify and differentiate rotavirus
from other causes of diarrhea and information on how to
manage it accordingly.
Mixed feelings towards the use of the vaccine
While most of the physicians believed that the vaccine
was important and cost effective when compared to
current treatments, some of the nurses/midwives felt
that it would be better to use other approaches such as
improved hygiene and access to clean water.
“Actually diarrhea can be prevented, right, do not
have to be given the vaccine. It is the factors of hygiene
normally, so I think it is not very important as long as
we are clean” (Nurse)
The fact that the vaccine had not been included on the
NIP led some people to believe that the Indonesian gov-
ernment also questioned the importance of vaccinating
the community against rotavirus.
“If the vaccine is not included in national programs
yet, it must be not too important. Because the
government should include the important things first
into the program” (Midwife)
Participants proposed that the vaccine could be rec-
ommend to ‘rich people’ so they can purchase it, while
lower socioeconomic groups could be educated about
cleanliness. Overall, it was suggested that members of
the public would accept the vaccine as long as it was on
the NIP, with the rational that members of the public are
usually very welcoming of new vaccines on the NIP.
The vaccine is too expensive
The current cost of the vaccine was considered to be the
biggest barrier in promoting the use of the rotavirus vac-
cine in Indonesia. Midwives and physicians thought that it
would be difficult to persuade people to vaccinate their
children if the vaccine was not affordable. Vaccine cost
would mostly impact those in the low socioeconomic
levels as people in the middle and higher income groups
would be able to afford the vaccine. One physician felt
that the government hadn’t considered the vaccine afford-
ability or a strategy for communicating the need for the
vaccine to the general public.
“Usually they will be happy when they know the
purpose but then when they found out about the price,
they will be sad. So usually they won’t get it.”
(Midwife)
“They actually think about the cost more than
anything here. If it’s for free, I’m sure they will get it
but if they have to pay, they will rethink on it, even
though they know it’s good for their children”.
(Pediatrician)
However, not all participants agreed that price of the
vaccine was a big issue as reflected by the words of a
pediatrician below:
“Price in my opinion is relative. If we educate the
parents well, then even if it’s expensive, it will be just
perfectly fine with them. But if we wrongly educate
them, even though it’s cheap, people will not buy it.
One proof is with DPT vaccine, it was R450.000 but
now it is being used daily here and there are demands
and the demands come from middle class. So I think
it’s not a problem, depends on how we educate. The
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community does care about their children, if that’s
what they need then no matter what they will get it.
(Pediatrician)
They suggested that including the vaccine into NIP
could solve this problem.
Issues impacting on acceptance
A lack of awareness about the potential seriousness of
diarrhea, about rotavirus and the availability of the vac-
cine was also postulated as a barrier. It was suggested
that not only do members of the community lack know-
ledge about the pathogen and the vaccine, but also
health professionals are unsure. Amongst the midwives
who reported being reluctant to recommend the vaccine,
a lack of knowledge was cited as the primary reason for
not recommending it. This is reflected in the comments
made by a midwife:
“I have no courage to recommend it. If the parents
asked further, I’m afraid I can’t answer because I don’t
understand it yet. But I have recommended them for
MMR and Hib vaccine.” (Midwife)
The majority of the participants noted the issue of the
vaccine not being ‘halal’ (An Arabic word meaning law-
ful or permitted). Many accepted the need for the vac-
cine but highlighted that the vaccine would not be
accepted as it is ‘haram’ (The opposite of halal is haram,
which means unlawful or prohibited). Participants noted
that the vaccine must have the official label from the
Majelis Ulama Indonesia (MUI).
“Principally, I agree with the immunization, but the
problem is that during this time, the vaccine is
contaminated with pig enzyme”. (Pediatrician)
It was also suggested that members of the community
downplay their religious concerns about the vaccine in
order to avoid arguments with their physicians, instead
focusing on other vaccine concerns.
“When the problem is about religion, they often hide it,
but they tend to talk about the side effect as they have
read from the Internet. They don’t want to debate
about belief to the physicians” (Pediatrician)
Provider barriers to vaccination
From a provider perspective, participants suggested that
health professionals are too busy to promote the vaccine
and that during the consultations only has the time to
focus on discussing the NIP vaccines with parents. It
was also postulated that access to the vaccine in remote
areas is a problem affecting the use of the vaccine.
“We have too many patients to be immunized in a
single day (50–60 patients), so there is no time”.
(Midwife)
“service is not available everywhere. So if their house
are far away then they have to make effort just to go to
PHC is difficult decision for the parents to vaccinate
their children.” (Midwife)
Lastly, having sufficient quantities of vaccine (prefera-
bly locally manufactured) was also highlighted as being
important.
“The number one obstacle is production, where we are
not able to produce it yet. So like in the case of polio,
we did not have any until half a year and that’s a
huge obstacle in immunization. So if we do wish to put
it in the government’s program, make sure the
production is good, better if we can make it on our
own”. (Pediatrician)
Important to work with local leaders and to use mass
media
The need to work with local public health officers, reli-
gious leaders and local government leaders to promote the
need for the vaccine was highlighted in most of the inter-
views. One pediatrician suggested that it would be a good
idea to take the religious leaders through the vaccine
manufacturing process, so that they can issue a certificate
which states that the vaccine is ‘halal’ in order to make it
acceptable to patients. One participant even went as far as
to suggest that the Sultan (King and Governor of
Yogyakarta) should be involved.
“The involvement of the mayor, regent, headman etc. is
extremely important. I wish the Sultan would just say
that all the citizens are required to be vaccinated with
the rotavirus vaccine. I’m sure no one will refuse,
especially if someone attends him from the MUI who
explains about the halalness of this vaccine and also
someone from the drug company making this vaccine
and also a physician who explains about the danger
from rotavirus infection. I’m sure no one within the
community will dare to refuse, but no such thing ever
happens” (Pediatrician)
“The capacity to explain and the tupoksi
(responsibility) are with the health service office,
puskesmas, then the cadres or public figures. Those
cross-sectorial people should be involved here. So, we
cannot work alone; it is difficult” (Physicians)
Advertising on local television and in local newspapers
was suggested as the most effective approaches for reaching
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people in remote areas. In addition, it was proposed that
seminars and counselling at mothers meetings be con-
ducted to educate people about the vaccine. Given that not
all members of the community are literate, it is important
that local health cadres also verbally promote the messages
about the disease and the vaccine.
Discussion
From the interviews we identified that diarrhea is not al-
ways rated as an important problem in Indonesia, but
participants do acknowledge that it can be serious if not
properly treated. While there was some level of know-
ledge about rotavirus, very few participants knew that a
vaccine was available. Lastly, there were some who be-
lieved that vaccination against rotavirus was unnecessary
given the fact that there are alternative approaches to
preventing diarrhea.
In 2007, Simpson et al. undertook interviews with
public health providers about in rotavirus in five low-
and middle-income countries including Indonesia [7]. In
corroboration with our study, they also reported that in
all five settings, knowledge of rotavirus was extremely
low and their participants also ranked the disease as not
being a high priority. In Indonesia, the rotavirus vaccine
is currently only available in pediatricians’ private prac-
tices. It is therefore not unexpected that the midwives
participating in our study had very little knowledge and
awareness about the vaccine given that they all worked
in public primary health centers. Amongst the midwives
who reported being reluctant to recommend this vaccine
they cited lack of knowledge as the main reason.
Mixed levels of support for the rotavirus vaccine have
been reported in high-resource settings [8, 9]. In low/mid-
dle income settings, very few studies have been undertaken
to examine the attitudes of HCPs towards the use of the
rotavirus vaccine. One survey of Indian pediatricians identi-
fied that over 70 % are using the rotavirus vaccine select-
ively, while only 9.7 % administer it routinely and 16 % do
not administer it at all. Interestingly, only 62.1 % of their
participants believed that rotavirus disease would be severe
in an infant and only 24.3 % felt it would be severe in a
child aged 1–5 years. Lastly, only 45 % reported that they
believed that the rotavirus vaccine was efficacious [10].
This is an important finding given the fact that the atti-
tudes of health professionals are major factor associated
with vaccine uptake [11]. In order to promote the use of
the vaccine, communication messages need to be clearly
defined and directed. Information must be provided to all
types of HCPs including midwives, nurses and physicians
about the burden of disease, the epidemiology of rotavirus
in Indonesia, the cost of disease vs. the cost of vaccination,
safety and effectiveness associated with the vaccine and the
rationale for vaccination. It is important that the education
messages break down the misconceptions around diarrhea
and rotavirus especially. For example, we found that partic-
ipants believed that improved hygiene and cleanliness
would prevent cases of rotavirus diarrhea. However, we
know rates of rotavirus diarrhea are universally similar
(pre-vaccine) indicating that hygiene practices do not
reduce transmission of rotavirus.
While the attitudes of providers and parents will impact
on the use of the vaccine, one of the biggest barriers is
ultimately the cost of the vaccine. In Indonesia the price of
the vaccine is between US$17–$23 per dose on the private
market. While this is not the most expensive vaccine avail-
able on the private market (Pentavalent DTPa-HBV-Hib
and pneumococcal vaccines cost between US$30–$58 per
dose), it is unlikely that some community members will opt
to purchase this vaccine. Participants proposed that the
vaccine needs to be added to the NIP and then both com-
munity members and HCPs would accept it. The most ef-
fective way to ensure maximum uptake of vaccination is to
provide reimbursement for the vaccine within a NIP [12].
A 2013 Indonesian economic evaluation indicated that
the rotavirus vaccination program would be cost-neutral
at a price of US$2.39–3.01 (health-care perspective) to
US$3.45–4.13 (societal perspective). If the rotavirus vac-
cine could be administered for US$2.70 or less per course
it would be potentially cost saving from the Indonesian
health-care perspective and at US$3.79 or less per course
as cost saving from a societal perspective. Even at a price
of US$ 14 per course, rotavirus immunization would be
highly cost-effective given Indonesia’s GDP [13].
Indonesia has the largest Muslim population of any
country—212 million of its 241 million people (88 percent)
[14]. Some members of Islamic faith may object to receiv-
ing the rotavirus vaccine, arguing that it is “haram” (not
permitted) as porcine products are used in the manufactur-
ing process as highlighted by our participants. However,
scholars of the Islamic Organization for Medical Sciences
in conjunction with the WHO have determined that the
transformation of pork products into gelatin sufficiently
alters them, thus making it permissible for observant
Muslims to receive vaccines containing gelatin [15]. In
Indonesia, the primary Muslim groups including mem-
bers from Majelis Ulama Indonesia (Indonesia’s top
Muslim clerical body), Muhammadiyah and Nahdlatul
Ulama (Independent Islamic organizations), attended a
workshop in 2011 and agreed that the rotavirus vaccine
should be considered as halal. Despite this, the vaccines
currently available in Indonesia are yet to receive the official
symbol on the label. Participants reported that lengthy
explanations about the production of the vaccine are un-
necessary as parents are happy enough to just be shown the
symbol on the vial. While there is uncertainty whether this
will happen, HCPs should be reminded that the rotavirus
vaccine is routinely used in many other majority-Muslim
countries including Malaysia, Bangladesh, Saudi Arabia and
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Egypt [16]. In addition, the rotavirus vaccines available
in Indonesia, the monovalent human rotavirus vaccine
(RotarixTM, GlaxoSmithKline), received halal certification
in June 2014 from the European Union Halal Food Council
of Europe (HFCE), while the bovine backbone vaccine
(RotateqTM, Merck &Co) received halal certification in in
2013 by the Islamic Food and Nutrition Council of America
(IFANCA).
The use of in-depth interviews to elicit a greater depth
in the information is a key strength of our work. However,
we acknowledge that there are limitations associated with
our work. Firstly, interviews were only undertaken with a
small select group of HCPs from two selected geographic
locations, so the possibility of other important themes
emerging cannot be ruled out. The application of our find-
ings to a broader population may be limited due to the
unique characteristics of our study sample. This may have
also been heightened by the fact that some of the partici-
pants were unaware of the vaccine prior to their involve-
ment in the study. Large quantitative surveys should be
undertaken with a representative sample of HCPs to verify
the findings from our study. The use of in-depth inter-
views are an important way of identifying important issues
around the use of the rotavirus vaccine and our study has
shed further light on the barriers to rotavirus vaccination.
Conclusion
The current cost of the rotavirus vaccines in the private
market and the low priority given to this vaccine are the
biggest obstacles impacting on the adoption of this vac-
cine in Indonesia. Disease burden is universally consid-
ered to be an important driver of decisions to adopt new
vaccines. HCPs need to be reminded of the burden of
disease associated with rotavirus, the costs coupled with
treating cases as compared to the costs associated with
preventing cases may also assist with improving accept-
ance towards the vaccine. In addition, providers and
consumers need to be reminded that there are no rem-
nants of porcine products remaining in the final vaccine.
Promotion campaigns need to target the range of HCPs
involved with providing care to pregnant women and
young children.
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